Open AccessLong-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab
Author(s) -
Elaine M. Sloand,
Matthew J. Olnes,
Barbara Weinstein,
Colin O. Wu,
Jaroslaw P. Maciejewski,
Phillip Scheinberg,
Neal S. Young
Publication year - 2010
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2009.013557
Subject(s) - daclizumab , medicine , pure red cell aplasia , aplastic anemia , anemia , gastroenterology , aplasia , blood transfusion , surgery , transplantation , bone marrow , tacrolimus
Pure red cell aplasia and moderate aplastic anemia are marrow failure states with an immune pathogenesis. Previously, we described short-term improvements in blood counts in two pilot studies treating moderate aplastic anemia (mAA) and pure red cell aplasia (PRCA) patients with daclizumab, a humanized monoclonal antibody to the interleukin-2 receptor; we now report our long-term experience with a larger cohort of patients.